Shanghai Universal Biotech Co.,Ltd. (SHE:301166)
China
· Delayed Price · Currency is CNY 33.62
+0.88 (2.69%)
At close: Mar 10, 2026
SHE:301166 Revenue
Shanghai Universal Biotech had revenue of 271.23M CNY in the quarter ending September 30, 2025, a decrease of -1.45%. This brings the company's revenue in the last twelve months to 1.07B, down -8.67% year-over-year. In the year 2024, Shanghai Universal Biotech had annual revenue of 1.12B, down -8.82%.
Revenue (ttm)
1.07B
Revenue Growth
-8.67%
P/S Ratio
2.70
Revenue / Employee
1.63M
Employees
698
Market Cap
2.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.12B | -108.07M | -8.82% |
| Dec 31, 2023 | 1.23B | 30.70M | 2.57% |
| Jan 1, 2023 | 1.20B | 85.46M | 7.70% |
| Jan 1, 2022 | 1.11B | 260.59M | 30.69% |
| Dec 31, 2020 | 849.08M | 62.15M | 7.90% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Shandong Sito Bio-technology | 954.76M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Novoprotein Scientific | 151.51M |
| Landfar Bio-medicine | 125.47M |
| Shanghai Serum Bio-Technology | 196.21M |
| Suzhou Fushilai Pharmaceutical | 439.57M |
| Zhejiang East Asia Pharmaceutical | 831.56M |